Literature DB >> 9366712

Emerging evidence of selection of fluconazole-tolerant fungi in surgical intensive care units.

T G Gleason1, A K May, D Caparelli, B M Farr, R G Sawyer.   

Abstract

OBJECTIVE: To determine whether increased use of fluconazole has coincided with a shift in the relative proportion of fluconazole-tolerant species isolated from critically ill surgical patients in 2 university hospitals.
DESIGN: Microbiological data and fluconazole administration frequencies were reviewed among patients treated in the surgical intensive care units (SICUs) from January 1, 1990, through December 31, 1995.
SETTING: The SICUs of the University of Virginia Medical Center, Charlottesville, and the Hospital of the University of Pennsylvania, Philadelphia. MAIN OUTCOME MEASURES: The number and species types of all fungal isolates and the number of patients treated with fluconazole for each of the 6 years were determined.
RESULTS: A sharp increase in the use of fluconazole among critically ill surgical patients has occurred at both medical centers from 1990-1995. The culture results of most patients treated with fluconazole were negative for fungi (73% and 63% at the University of Virginia Medical Center and the Hospital of the University of Pennsylvania, respectively); there was a greater tendency to use fluconazole at the University of Virginia Medical Center compared with the Hospital of the University of Pennsylvania (2.2% vs 1.8% of patients admitted to the SICU received it, respectively; P = .007). There was a significant increase in the proportion of Candida glabrata isolated at the University of Virginia Medical Center (P < .01) from 1990-1995, but a similar change was not detectable at the Hospital of the University of Pennsylvania.
CONCLUSIONS: These data justify concern that the increased use of fluconazole in SICUs may be promoting a shift in the fungal flora that cause nosocomial infections toward species that are more difficult to treat. Prospective studies about the use of fluconazole for prophylaxis and empirical therapy among SICU patients are warranted before its widespread use in these settings continues.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9366712     DOI: 10.1001/archsurg.1997.01430350047008

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  18 in total

1.  Polymorphic internal transcribed spacer region 1 DNA sequences identify medically important yeasts.

Authors:  Y C Chen; J D Eisner; M M Kattar; S L Rassoulian-Barrett; K Lafe; U Bui; A P Limaye; B T Cookson
Journal:  J Clin Microbiol       Date:  2001-11       Impact factor: 5.948

2.  Identification of medically important yeasts using PCR-based detection of DNA sequence polymorphisms in the internal transcribed spacer 2 region of the rRNA genes.

Authors:  Y C Chen; J D Eisner; M M Kattar; S L Rassoulian-Barrett; K LaFe; S L Yarfitz; A P Limaye; B T Cookson
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

3.  Correlation between microdilution, E-test, and disk diffusion methods for antifungal susceptibility testing of posaconazole against Candida spp.

Authors:  Charles R Sims; Victor L Paetznick; Jose R Rodriguez; Enuo Chen; Luis Ostrosky-Zeichner
Journal:  J Clin Microbiol       Date:  2006-06       Impact factor: 5.948

4.  Candida spp. colonization significance in critically ill medical patients: a prospective study.

Authors:  Pierre Emmanuel Charles; Frédéric Dalle; Hervé Aube; Jean Marc Doise; Jean Pierre Quenot; Ludwig Serge Aho; Pascal Chavanet; Bernard Blettery
Journal:  Intensive Care Med       Date:  2005-02-12       Impact factor: 17.440

Review 5.  Clinical, cellular, and molecular factors that contribute to antifungal drug resistance.

Authors:  T C White; K A Marr; R A Bowden
Journal:  Clin Microbiol Rev       Date:  1998-04       Impact factor: 26.132

Review 6.  Systematic review and meta-analysis of antifungal agents for preventing fungal infections in liver transplant recipients.

Authors:  E G Playford; A C Webster; T C Sorrell; J C Craig
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-09       Impact factor: 3.267

7.  The ATP binding cassette transporter gene CgCDR1 from Candida glabrata is involved in the resistance of clinical isolates to azole antifungal agents.

Authors:  D Sanglard; F Ischer; D Calabrese; P A Majcherczyk; J Bille
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

8.  Prior antimicrobial therapy and risk for hospital-acquired Candida glabrata and Candida krusei fungemia: a case-case-control study.

Authors:  Michael Y Lin; Yehuda Carmeli; Jennifer Zumsteg; Ernesto L Flores; Jocelyn Tolentino; Pranavi Sreeramoju; Stephen G Weber
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

9.  Outcomes associated with routine systemic antifungal therapy in critically ill patients with Candida colonization.

Authors:  David Ferreira; Frederic Grenouillet; Gilles Blasco; Emmanuel Samain; Thierry Hénon; Alain Dussaucy; Laurence Millon; Mariette Mercier; Sebastien Pili-Floury
Journal:  Intensive Care Med       Date:  2015-04-18       Impact factor: 17.440

10.  Inactivation of transcription factor gene ACE2 in the fungal pathogen Candida glabrata results in hypervirulence.

Authors:  Mohammed Kamran; Ana-Maria Calcagno; Helen Findon; Elaine Bignell; Michael D Jones; Peter Warn; Philip Hopkins; David W Denning; Geraldine Butler; Thomas Rogers; Fritz A Mühlschlegel; Ken Haynes
Journal:  Eukaryot Cell       Date:  2004-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.